Slow Heartbeat: Drugs That Cause or Treat Bradycardia

What Bradycardia Actually Means

Bradycardia is a resting heart rate below 60 beats per minute. The 2018 ACC/AHA/HRS guideline on bradycardia defines it this way and distinguishes between physiologic bradycardia (common in trained athletes and during sleep) and pathologic bradycardia, which produces symptoms like dizziness, fatigue, syncope, or exercise intolerance [1].

Not every slow pulse needs treatment. Endurance athletes routinely record resting rates in the 40s without any symptoms at all. The clinical question is always whether the slow rate is causing hemodynamic compromise. A heart rate of 48 bpm in a 25-year-old marathon runner is normal physiology. That same rate in a 72-year-old on three rate-lowering medications who keeps passing out is a medical problem requiring intervention [1].

Sinus node dysfunction and atrioventricular (AV) conduction block account for most structural causes. But in practice, medications are among the most frequent and most reversible triggers. A 2019 retrospective cohort study at a single academic medical center found that drug-related bradycardia accounted for roughly 28% of all bradycardia admissions [2]. Identifying and discontinuing the offending agent is the first step before any escalation.

Drugs That Cause Slow Heartbeat

The pharmacologic causes of bradycardia fall into a few predictable categories. Each works through a different mechanism on the cardiac conduction system.

Beta-adrenergic blockers are the single most common drug class associated with bradycardia. Metoprolol, atenolol, carvedilol, and propranolol all reduce heart rate by blocking sympathetic stimulation of the sinoatrial (SA) node. A meta-analysis of 56 randomized trials (N=137,715) published in the BMJ found that beta-blockers reduced mean heart rate by 10.7 bpm compared with placebo, and symptomatic bradycardia occurred in 4.6% of patients [3]. The risk increases with higher doses, renal impairment, and concurrent use of other rate-slowing agents.

Non-dihydropyridine calcium channel blockers, specifically diltiazem and verapamil, slow conduction through the AV node. These drugs are frequently prescribed for rate control in atrial fibrillation. Diltiazem at doses above 240 mg/day carries a clinically meaningful bradycardia risk: the DILACOR trial reported heart rates below 50 bpm in 3.3% of patients on extended-release diltiazem versus 1.1% on placebo [4].

Digoxin slows the heart through vagotonic effects and direct depression of AV node conduction. It has a narrow therapeutic window: serum concentrations above 2.0 ng/mL are associated with a greater than 50% probability of bradyarrhythmia, per data from the Digitalis Investigation Group (DIG) trial [5]. The 2014 AHA/ACC heart failure guideline recommends maintaining serum digoxin between 0.5 and 0.9 ng/mL to minimize toxicity risk [6].

Antiarrhythmic agents present a particular hazard. Amiodarone causes sinus bradycardia in 2 to 5% of patients and can persist for weeks after discontinuation due to its 40-to-55-day half-life [7]. Sotalol, flecainide, and dronedarone each carry their own bradycardia profiles. The ACC/AHA/HRS 2018 guideline specifically warns clinicians to monitor heart rate in patients started on Class I or III antiarrhythmics [1].

Other notable offenders include clonidine (central alpha-2 agonist), lithium, donepezil (cholinesterase inhibitor used in Alzheimer disease), and ivabradine, which directly inhibits the funny current (If) in the SA node and is designed to lower heart rate. Opioids, particularly fentanyl and remifentanil, also depress heart rate through vagal mechanisms [8].

How Clinicians Identify the Culprit Drug

The diagnostic workup begins with a 12-lead electrocardiogram. Sinus bradycardia shows a regular rhythm with P waves preceding every QRS complex, just at a rate below 60 bpm. AV block patterns (first-degree, second-degree Mobitz I or II, third-degree) point to conduction system disease, which may be drug-induced or structural.

A medication reconciliation is the single most productive step. The 2018 ACC/AHA/HRS guideline states: "In patients with bradycardia, it is recommended to assess for and manage reversible causes such as medication effects" as a Class I recommendation [1]. This means stopping or dose-reducing the offending drug before pursuing any device-based therapy.

Serum drug levels matter for specific agents. Digoxin levels, thyroid function tests (hypothyroidism is a common non-drug cause), and electrolyte panels (hyperkalemia slows conduction) should be checked in any new-onset bradycardia workup [9]. Ambulatory Holter monitoring over 24 to 48 hours helps capture intermittent bradycardia that may not appear on a single ECG.

Electrophysiology studies are reserved for cases where the mechanism remains unclear after non-invasive evaluation. These studies can measure sinus node recovery time and AV conduction intervals to localize the site of dysfunction. Most drug-induced cases resolve without reaching this step.

First-Line Emergency Treatment: Atropine

When bradycardia produces hemodynamic instability (hypotension, altered mental status, signs of shock, or acute heart failure), treatment must be immediate. The American Heart Association's Advanced Cardiovascular Life Support (ACLS) protocol places atropine as the first-line agent [10].

Atropine works by blocking vagal input to the SA node. The recommended dose is 0.5 mg IV, repeated every 3 to 5 minutes up to a maximum of 3 mg. Doses below 0.5 mg should be avoided because paradoxical further slowing can occur through a central vagotonic effect [10].

Atropine has limits. It is ineffective in patients with infranodal (Mobitz II or third-degree) AV block because the block sits below the level of vagal innervation. In a retrospective analysis of 235 patients with symptomatic bradycardia in the emergency department, atropine restored adequate heart rate in 67% of sinus bradycardia cases but only 38% of complete heart block cases [11]. For these patients, transcutaneous pacing is the bridge.

Dr. Mark Link, a cardiac electrophysiologist formerly at Tufts Medical Center and now at UT Southwestern, has noted: "Atropine buys you time. It does not fix the underlying problem. If the bradycardia is drug-induced, the drug needs to come off. If it is structural, the patient needs a pacemaker."

Pharmacologic Bridges When Atropine Fails

If atropine does not restore an adequate heart rate and transcutaneous pacing is not immediately available, two pharmacologic agents serve as bridges.

Dopamine at 5 to 20 mcg/kg/min acts on beta-1 adrenergic receptors to increase heart rate and contractility. The ACLS algorithm includes it as a second-line agent for symptomatic bradycardia [10]. Infusion rates above 10 mcg/kg/min also produce alpha-mediated vasoconstriction, which supports blood pressure but increases afterload.

Isoproterenol is a non-selective beta-agonist that directly increases SA node automaticity and AV conduction. It is given as a continuous infusion at 2 to 10 mcg/min. Its use has declined over the past two decades because of the risk of triggering ventricular arrhythmias, but it remains in the ACLS toolkit for refractory bradycardia pending pacemaker placement [10].

Glucagon deserves specific mention for beta-blocker or calcium channel blocker overdose. It activates adenylyl cyclase through a non-adrenergic pathway, bypassing the blocked beta receptors entirely. The recommended dose is 3 to 10 mg IV bolus followed by an infusion of 3 to 5 mg/hour. A case series from the American Association of Poison Control Centers (N=412) reported heart rate improvement in 58% of patients with beta-blocker toxicity treated with glucagon [12].

For digoxin-specific toxicity, digoxin immune Fab (Digibind or DigiFab) is the targeted antidote. The DIG trial and subsequent pharmacovigilance data support its use when serum digoxin exceeds 2.0 ng/mL with symptomatic bradycardia or ventricular arrhythmias [5]. Each vial binds approximately 0.5 mg of digoxin, and dosing is calculated based on estimated total body digoxin load.

Permanent Pacemakers: When Drugs Alone Are Not Enough

The 2018 ACC/AHA/HRS guideline provides a Class I recommendation for permanent pacemaker implantation in patients with symptomatic bradycardia that is not attributable to a reversible cause [1]. The key word is "reversible." Drug-induced bradycardia should resolve with medication withdrawal. If symptoms persist after the offending drug has been cleared for at least five half-lives, structural conduction disease is likely present, and pacing becomes appropriate.

Over 200,000 pacemakers are implanted annually in the United States, according to data from the National Cardiovascular Data Registry [13]. The most common indications are sinus node dysfunction (about 50% of implants) and AV block (about 35%).

Dr. Fred Kusumoto, who chaired the 2018 ACC/AHA/HRS bradycardia guideline writing committee, stated in the guideline document: "The decision to implant a permanent pacemaker should be made only after establishing a clear correlation between symptoms and bradycardia and after exclusion of reversible causes" [1].

Dual-chamber pacemakers (DDD mode) are standard for most patients because they preserve AV synchrony. Single-lead ventricular (VVI) pacing is reserved for patients with permanent atrial fibrillation and slow ventricular response. Leadless pacemakers (such as the Medtronic Micra) offer an alternative for selected patients, with a 96.0% freedom from major complications at 12 months in the Micra Transcatheter Pacing Study (N=725) [14].

Drugs That Intentionally Slow the Heart

Some of the same agents that cause problematic bradycardia are prescribed deliberately for rate control. Context determines whether the slow heart rate is a therapeutic goal or a side effect.

Beta-blockers remain first-line therapy for rate control in atrial fibrillation. The RACE II trial (N=614) demonstrated that lenient rate control (resting heart rate target below 110 bpm) was non-inferior to strict control (below 80 bpm) for cardiovascular outcomes over three years, which has shifted practice toward accepting higher target rates [15]. This means clinicians now have more room to avoid pushing doses into bradycardia territory.

Ivabradine is unique. It was developed specifically to lower heart rate without affecting blood pressure or contractility. The SHIFT trial (N=6,558) showed that ivabradine reduced the composite of cardiovascular death or heart failure hospitalization by 18% in patients with heart failure and a resting heart rate at or above 70 bpm (HR 0.82 to 95% CI 0.75-0.90, P<0.0001) [16]. The FDA approved it in 2015 for symptomatic heart failure with a resting rate of 70 bpm or higher despite maximally tolerated beta-blocker therapy.

Amiodarone, while causing problematic bradycardia in some patients, is the preferred antiarrhythmic for ventricular tachycardia and fibrillation in the acute setting. Its rate-slowing effect is sometimes a desired secondary outcome in patients with rapid atrial fibrillation.

Special Populations and Risk Factors

Elderly patients carry the highest risk for drug-induced bradycardia. Age-related fibrosis of the conduction system reduces the functional reserve of the SA and AV nodes, making these structures more vulnerable to pharmacologic suppression. A population-based study using Medicare claims data (N=428,067) found that patients aged 75 and older were 2.4 times more likely to be hospitalized for bradycardia while on rate-controlling medications compared to those aged 65 to 74 [17].

Renal impairment prolongs the half-lives of renally cleared drugs like atenolol, sotalol, and digoxin. Dose adjustment based on creatinine clearance is not optional in these patients. The Cockcroft-Gault equation or CKD-EPI formula should guide dosing decisions.

Drug-drug interactions multiply the risk. Combining a beta-blocker with verapamil or diltiazem is a well-known cause of severe bradycardia and is explicitly cautioned against in the ACC/AHA atrial fibrillation management guideline [18]. Adding amiodarone to a beta-blocker regimen requires heart rate monitoring within the first 72 hours at minimum.

Hypothyroidism, hyperkalemia, and increased intracranial pressure are non-drug causes that can compound medication effects. Any patient presenting with new bradycardia while on rate-controlling drugs should have thyroid function and electrolytes checked to rule out additive causes [9].

Stopping the Offending Drug Safely

Abrupt discontinuation of beta-blockers can trigger rebound tachycardia and, in patients with coronary artery disease, provoke angina or even myocardial infarction. The standard approach is to taper the dose over 7 to 14 days while monitoring heart rate and blood pressure [3].

Calcium channel blockers can generally be stopped more quickly because rebound is less pronounced, though monitoring remains appropriate. Digoxin can simply be held; its long half-life (36 to 48 hours in patients with normal renal function) means the effect will wane gradually without active tapering.

For patients who need the offending drug for another indication (a beta-blocker for heart failure, for example), the clinical team faces a risk-benefit decision. Reducing the dose, switching to a more selective agent, or adding a pacemaker to allow continued medication use are all viable strategies. The 2018 guideline explicitly addresses this scenario, stating that pacemaker implantation is reasonable (Class IIa) when a necessary medication causes symptomatic bradycardia that cannot be managed by dose reduction or substitution [1].